Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection

• Główni autorzy: Laura Whitney (Autor), John Nesnas (Autor), Timothy Planche (Autor)
• Format: Książka
• Wydane: MDPI AG, 2023-01-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Fidaxomicin, a macrocyclic antibiotic, selectively kills <i>Clostridioides difficile</i> and reduces <i>C. difficile</i> infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective. The aim of this study...